Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)

CNY 7.86

(0.51%)

Market Cap (In CNY)

3.75 Billion

Revenue (In CNY)

364.17 Million

Net Income (In CNY)

-398.89 Million

Avg. Volume

11.48 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.41-10.38
PE
-
EPS
-
Beta Value
0.501
ISIN
CNE100001237
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Wang Chao
Employee Count
-
Website
https://www.staidson.com
Ipo Date
2011-04-15
Details
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.